Concerning exempting certain drugs from the scope of affordability reviews conducted by the Colorado prescription drug affordability review board.
Summary
SB26-140 would limit the authority of the Colorado Prescription Drug Affordability Review Board by excluding certain prescription drugs from affordability reviews and from any resulting upper payment limits. Under the bill, the board could not review or set payment limits for drugs derived in whole or in part from cannabis, drugs designated by the FDA as treatments for rare diseases or conditions, or licensed biological products derived from human whole blood or plasma as identified on FDA-approved labeling.
The bill also directs the board to rely on FDA product information, including the approved blood products website and the list of fractionated plasma products, when determining whether a product qualifies for the blood- or plasma-derived exemption. The measure is framed as an amendment to Colorado’s existing prescription drug affordability statute and would narrow the scope of the board’s oversight rather than create a new regulatory program.
Impact
If enacted, the bill would amend Colorado Revised Statutes section 10-16-1415 to carve out three categories of drugs from the Prescription Drug Affordability Review Board’s review and upper-payment-limit authority. That would reduce the board’s reach over cannabis-derived drugs, orphan drugs for rare diseases or conditions, and certain biologic products made from human whole blood or plasma. The practical effect would be to shield those products from state affordability interventions that could otherwise affect pricing and reimbursement.
Sentiment
The available legislative history suggests the bill did not advance in the House, where it was postponed indefinitely in the House Committee on Health & Human Services. No committee transcript or recorded vote is provided, so there is little direct evidence of debate in the materials supplied. The bill’s sponsorship from members of both parties suggests at least some bipartisan interest in narrowing the board’s authority, but the final committee action indicates insufficient support to move it forward.
Contention
The main point of contention is the scope of the Prescription Drug Affordability Review Board’s power versus the desire to exempt certain specialized drugs from state price review. Supporters likely view the exemptions as protecting access to rare-disease therapies and complex biologics, and as avoiding unintended consequences for cannabis-derived medicines and plasma products. Opponents, or those who favored postponement, may have been concerned that carving out categories of high-cost drugs would weaken the board’s ability to address affordability for patients and payers. The absence of transcripts limits identification of specific arguments or speakers.